Canine Visceral Leishmaniasis ( 31-Mar-2000 )

Transcription

1 In: Recent Advances in Canine Infectious Diseases, L. Carmichael (Ed.) Publisher: International Veterinary Information Service ( Ithaca, New York, USA. Canine Visceral Leishmaniasis ( 31-Mar-2000 ) D. Strauss-Ayali and G. Baneth School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel. Introduction Visceral leishmaniasis is an infectious disease transmitted by sandflies, and caused by various species of Leishmania parasites. Distinct species occur in parts of the Old World and New World, and can infect people, domestic and wild animals. These parasites cause a wide spectrum of diseases in people, and it is estimated that the annual occurrence of human visceral leishmaniasis (HVL) cases worldwide is 500,000 [1]. Infection with Leishmania is also a frequent cause of clinical disease in the dog, especially in tropical, sub-tropical and temperate areas, and is less common in cats. According to the human clinical criteria, canine leishmaniasis is classified as visceral [2], although the term "generalized canine leishmaniasis" might be more appropriate because it involves visceral and cutaneous tissues. Etiology Leishmania is a genus of protozoa of the order Kinetoplastida, and family Trypanosomatidae. Leishmania parasites are diphasic protozoan parasites whose life cycle includes two hosts, a vertebrate (rodents, canids or humans), and an insect (sandfly)(fig. 1). Canine visceral leishmaniasis (CVL) in the Old World is the result of infection with Leishmania infantum, which is considered a distinct species [3] included in the L. donovani complex or creating its own complex [4]. However, it has also been considered as a subspecies, L. donovani infantum [5]. Recently, L. tropica was found to be the cause of a case of CVL in Morocco [6]. In the New World, Leishmania chagasi is considered as the cause of CVL. L. chagasi is currently thought to be synonymous to L. infantum based on a variety of genetic methods [7]. The low genetic variability of L. chagasi is consistent with recent importation to the New World and it is thought that L. chagasi is the result of the introduction of dogs from Europe infected with L. infantum that arrived with settlers. L. infantum infections occur mainly in countries in the Mediterranean basin, the Middle East, and Portugal [8-13]. Sporadic cases have been reported in the northern parts of France, Switzerland and the Netherlands, regions in which no sandflies are found, and in other non-enzootic areas (United States and Canada) [14-16]. Infection with L. chagasi is found in Central and South America. Leishmania spp. that cause visceral leishmaniasis in dogs, cats, and humans are listed in Table 1. Figure 1. The life cycle of parasites causing visceral leishmaniasis (Courtesy of Dr. Carol Eisenberger and Prof. Yosef Schlein). - To view click on figure - Epidemiology The natural infection cycle of Leishmania parasites involves an insect vector. In Old World CVL the vectors are sandflies from the genus Phlebotomus, whereas in the New World the vectors are from the genus Lutozomyia. Sandflies have a limited flight range (few kilometers), and are generally most active at dawn and dusk, and in certain seasons. When a female sandfly feeds on an infected dog, it ingests the intracellular nonflagellated form, amastigotes, in macrophages. The released amastigotes transform to the flagellated form, the promastigotes (Fig. 2). The promastigotes attach to the sandfly's gut wall where they multiply, and within a few days, the gut is packed with promastigotes. When the female gets another blood meal after laying her eggs, promastigotes may be injected to the vertebrate host's skin. The promastigotes are then phagocytosed by skin macrophages, loose their flagella and multiply as amastigotes.

2 Figure 2. Leishmania infantum promastigotes. - To view click on figure - Table1: Geographical distribution and clinical manifestation of Leishmania spp. infecting dogs, cats and humans Clinical Manifestation Parasite Dogs Cats Humans Old World L. tropica CL a, VL b CL, (VL) L. donovani VL, (CL, PKDL c ) L. infantum VL DCL d VL (CL) New World L. brazilensis CL, MCL e CL, MCL L. chagasi VL VL (CL) L. mexicana CL CL, DCL, MCL The parenthesis indicates a less common clinical manifestation of the disease a Cutaneous leishmaniasis, b Visceral leishmaniasis, c Post -Kala azar dermal leishmaniasis, d Diffuse cutaneous leishmaniasis, e Mucocutaneous leishmaniasis. In many areas where HVL occurs, there is an enzootic or sylvatic transmission cycle involving wild canids (including feral and stray dogs), and domestic dogs [17] (Fig. 1). Other wild animals (rats and opossums), were reported to be infected with Leishmania but there is no current evidence concerning the role of these animals as reservoir. Anthroponotic transmission from human to human is found in visceral leishmaniasis caused by L. donovani and is prevalent in India and Sudan. Feline visceral leishmaniasis was described in sporadic cases [18-22], and therefore cats are not considered as an important reservoir for the infection of people. Pathogenesis Leishmania parasites multiply initially in macrophages at the site of infection. If the host fails to generate an effective protective immune response, the parasites disseminate from the skin and spread in mononuclear phagocytes to the bone marrow, spleen and liver, to cause a chronic, possibly fatal disease. Studies in murine models have determined that the generation of a protective immune response against leishmaniasis is T cells mediated, manifested by a strong proliferative response of peripheral blood lymphocytes to leishmanial antigens, and mediated by cytokines, such as interferon gamma (IFN-γ), and tumor necrosis factor alpha (TNFα), which are required for the activation of macrophages and killing of intracellular parasites [23-27]. Hence, the chronicity of the disease and the high mortality in untreated cases has been associated with diminished T cell response. Dogs with chronic experimental or natural L. infantum infection can be classified as asymptomatic apparently resistant to clinical disease, and symptomatic susceptible to the disease [28, 29]. It was shown that 3 years after experimental infection with L. infantum, asymptomatic dogs responded to L. infantum antigen both by lymphocyte proliferation assays in vitro and by the delayed-type hypersensitivity reaction, whereas no serum antibodies towards L. infantum antigen were detected [28]. Yet, symptomatic dogs failed to respond to cell mediated assays both in vitro and in vivo, and showed a significant humoral response. Another study likewise demonstrated the lack of specific T cell response to leishmanial antigen as the main feature of experimental and natural symptomatic infections [30]. In addition, L. infantum-infected macrophages are lysed in a major histocompatibility complex restricted manner by CD8 cells mostly, and also CD4 cells from asymptomatic dogs [31]. Significantly higher levels of IL-2 and TNFα were found in supernatants from stimulated peripheral mononuclear cells from asymptomatic dogs when compared with cells from symptomatic dogs [28]. Moreover, peripheral blood mononuclear cells (PBMC) from asymptomatic dogs produced IFN-γ upon parasite antigen-specific stimulation, whereas lymphocytes from symptomatic dogs did not [31]. These findings are in accordance with the observation that self resolving L. major infection in mice is mediated by Th1 cells, characterized by production of IFN-γ, TNF, IL-2, IL-3, IL-12 and IgG2, while chronic to fatal disease is mediated by Th2, which is featured by IL-3, IL-4, IL-5, IL-6, IL-9, IL-10 and IgG1 production [32]. A correlation between disease progression and the IgG isotype's levels in both experimental and natural L. infantum infections in dogs was

3 demonstrated both by ELISA and western blotting. Anti-Leishmania IgG1 antibodies were considerably higher in symptomatic compared to asymptomatic dogs [33, 34]. These observations can suggest that a dichotomous response to L. infantum infection exists in dogs, similar to that found with L. major in mice, but are controversial as other studies failed to demonstrate this trend as clearly [35, 36]. When clinical signs develop, lymphoid organs become depleted in the T cells regions, and the B cells zones proliferate. The overall proliferation of B cells, macrophages, plasma cells and the attraction of eosinophils, results in hepatosplenomegaly, generalized lymphoadenomegaly, and hyperglobulinemia. The increased production of immunoglobulins is non-protective and is potentially damaging. Some specific antibodies will opsonize amastigotes causing their phagocytosis by macrophages, enabling the parasite to continue multiplying in the cell. The most hazardous result of the uncontrolled B cell proliferation and the impaired T cell regulation is the production of large amounts of circulating immune complexes (CIC). Circulating immune complexes concentrations were significantly higher in dogs with naturally acquired Leishmania infection, than in uninfected control dogs [37]. Deposition of CIC in blood vessels walls may result in vasculitis, polyarthritis, uveitis and glomerulonephritis. CIC may also include cryoglobulins that precipitate in the blood vessels of the extremities and cause ischemic necrosis when exposed to cold temperature [21]. Autoantibodies may also be produced in leishmaniasis, and cause immune mediated thrombocytopenia and/or anemia. Thrombocytopenia, diminished colagen-induced platelet aggregation, prolonoged prothrombin time and increased fibrin degradation products (FDP) were found in dogs experimentally infected with Leishmania, and were suggested to be a result of a compensated DIC [38]. The generalized non-pruritic skin lesions observed in CVL are the result of the dissemination of L. infantum parasites throughout the body [39]. It has been suggested that generalized nodular lesions indicate a less effective immune response than that associated with generalized alopecia [40]. Signalment and History Dogs from all age groups, many breeds and both genders were found to be infected with leishmaniasis [14], although symptomatic infection is uncommon in young immature dogs. In a recent retrospective study, infected dogs ages ranged from nine months to 15 years, with a 5 years median [41]. The main complaints reported by owners in that study were skin lesions (50.6%) (Fig. 3, 4, 5, 6, 7) progressive loss of weight (25.3%), decreased appetite (16.5%), and exercise intolerance (10.8%). Other complaints reported in several studies include: depression, ocular signs, epistaxis, polyuria -polydipsia, diarrhea, vomiting, melena, sneezing, coughing, and lameness [41-43]. Figure 3. Massive skin exfoliation on the back of a L. infantum infected dog. - To view click on figure - Figure 4. Onychogryposis in canine visceral leishmaniasis. - To view click on figure - Figure 5. Ulcerative dermatitis of the hind leg of a dog infected with L. infantum. - To view click on figure -

4 Figure 6. Alopecia and exfoliative dermatitis on the pinna of a dog infected with L. infantum. - To view click on figure - Figure 7. Alopecia of the head of dog infected with L. infantum. - To view click on figure - Clinical Signs Clinical signs have been reported to appear 3 months to 7 years after infection [43]. The major clinical signs of CVL are described in Table 2, the most common skin lesions are listed in Table 3, and the ocular signs mentioned in Table 4. Table 2: Major clinical signs in CVL Major clinical signs seen in CVL Percentage from dogs with CVL Skin involvement 81-89% a,b Lymphadenomegaly % a,b,c Pale mucous membranes 58% a Ocular signs 18% c Emaciation \ Cachexia % a,b,c Splenomegaly % a,b,c Fever 4-36% b,c Epistaxis % a,c Arthropathies 3.2-4% a,c Ascites 1.3-3% a,c a [41] ; b [43]; c [42] Table 3: Major skin lesions in CVL Types of skin lesions seen in CVL Percentage from dogs with CVL Exfoliative dermatitis % a,c Ulcerations % a,c Onychogryposis\Abnormal nails % a,b,c Nasal hyperkeratosis 18.8% a Digital hyperkeratosis 14.1% a Nodules 2.3-6% a,c a [41] ; b [43]; c [42]

5 Table 4: Major ocular signs in CVL Types of ocular signs seen in CVL Percentage from dogs with CVL Conjunctivitis % a,b Blepharitis 12% a Keratitis 7.5% b Keratoconjunctivitis sicca 5.1% a Uveitis % a,b a [42]; b [43] Clinicopathologic Findings The typical clinicopathologic findings associated with CVL are listed in Table 5. Table 5: Major clinicopathological signs in CVL Clinicopathologic findings Percentage from dogs with CVL Hyperproteinemia % a,c Hyperglobulinemia % b,c Hypoalbuminemia 68-94% b,c Decreased albumin/globulin ratio 76% c Nonregenerative anemia % a,c Thrombocytopenia % b,c Leukocytosis 24% c Leukopenia 22% b Increased serum liver enzymes activities 16% c Elevated urea and creatinine 16-45% b,c Mild/severe proteinuria % a,b Hyaline/fine granular urine casts Approaching 100% a a [41] ; b [43]; c [42] Diagnosis Serology Dogs with CVL infection, either symptomatic or asymptomatic, will almost always demonstrate a specific humoral response. Therefore, various serological methods for the detection of anti-leishmania antibodies have been developed. These include indirect immunofluoresence assays (IFA), direct agglutiation assays (DAT), enzyme-linked immunosorbent assay (ELISA), competitive-elisa, Dot-ELISA, slide-elisa, and western blotting [40-47]. In general, good sensitivities and specificities are gained with these methods which are mostly based on the use of crude antigens. Seroreactivity with the recombinant antigen rk39 by ELISA [48], correlated well with the appearance of acute CVL [36, 49]. The use of crude Leishmania antigens is thought to underestimate the prevalence of CVL [50]. Purified Leishmania antigens for the diagnosis of CVL are of considerable importance in South America where cross-reactions were demonstrated between Leishmania spp. and trypanosomes. Diminishing antibody titers are not indicative of parasitological cure after treatment, although a decrease in the titer, and in the number and/or intensity of low molecular bands by western blot is coincidental with clinical improvement of treated dogs [51, 52].

6 Direct organism identification Cytology and histology - Leishmania amastigotes can be demonstrated in impression smears made from fine needle aspirates of lymph nodes, spleen or bone marrow, and stained with Giemsa stain or a quick stain such as Diff-Quick. Amastigotes are round to oval parasites, which contain a round basophilic nucleus, and a small rod-like kinetoplast. Amstigotes are contained within macrophages, or may be found free in cytologic preparations after freeing from ruptured cells. Impression smears can also be made from dermal lesions, such as those found on the tip of the ear, after scraping of the skin (Fig. 8). Figure 8. A Giemsa -stained impression smear obtained from the tip of the ear of a dog infected with L. infantum. Note the numerous intracellular and extracellular amastigotes. - To view click on figure - In vitro cultivation - Culture of aspirates from the spleen, lymph nodes, skin and bone marrow in Novy-MacNeal-Nicolle medium (NMN) or Schneider's Drosophila medium is used to identify patent infection and for further characterization of isolates. In vivo cultivation - Diagnosis may also be established by the inoculation of hamsters with infected tissues and monitoring their clinical signs. This technique is used mostly in research. Immunohistochemistry - An indirect peroxidase reaction using sera obtained from infected dogs was shown to be useful in the detection of L. infantum in formalin-fixed, paraffin-embedded sections of canine skin and lymph nodes [53]. Polymerase chain reaction (PCR) - Initial successful evaluation of a PCR for the identification of Leishmania spp. in lymph node aspirates and whole blood from dogs was performed using primers directed against a sequence of the small-subunit (SSU) rrna gene, which has more than a hundred repeats in the Leishmania genome [54]. When a PCR directed against the Leishmania spp. kinetoplast DNA (kdna) was compared with serology, it was more sensitive [55, 56], and demonstrated 100% sensitivity and specificity when lymph nodes aspirates were used, and 85% and 80%, respectively, with whole blood samples [56]. The same primers were also successful in identifying Leishmania spp.- specific DNA in paraffin-embedded skin biopsies from dogs [57]. Currently, PCR seems to be a sensitive and specific method for the diagnosis of CVL in dogs. Identification of Leishmania spp. The identification and characterization of Leishmania spp. is important in understanding the epidemiology and transmission of leishmaniasis. Isoenzyme analysis is the "gold standard" for strain characterization but is time consuming, since each isolate must be examined by multiple enzyme reactions [58]. PCR using kdna primers specific for New World or Old World species has been used successfully [55, 59], however, species-specific PCR requires the design of individual primer sets for each species and subspecies. Random amplified polymorphic DNA (RAPD), and arbitrary primer (AP)- PCR, based on fragment length polymorphism utilize nonspecific primers which give rise to a variety of amplification products [60, 61]. AP or RAPD-PCR can't be used for direct diagnosis because false positives can occur with host contaminating DNA. A newly developed PPIP (permissively primed intergenic polymorphic) -PCR can distinguish by simple means between Old World Leishmania spp. with no false positives due to host DNA contamination [62]. Treatment Human visceral leishmaniasis is commonly treated and cured in people that are not HIV+ with very high success rates. Antileishmanial drugs used in human therapy include pentavalent antimonials (selectively inhibit the protozoal enzymes required for glycolytic and fatty acid oxidation), aminosidine (an aminoglicoside antibiotic), pentamidine (interferes with nuclear metabolism), liposomal amphotericin B (a powerful anti-leishmanial agent), and allopurinol (a purine analogue). Canine visceral leishmaniasis is more resistant to therapy as compared to people and parasitological cure is rarely attained. As with humans, the most frequently used drugs for the treatment of CVL are pentavalent antimonials, such as meglumine antimoniate and sodium stibogluconate. The subcutaneous route of meglumine administration is the most commonly used, however, reported dose regimens for meglumine antimoniate vary from mg/kg IV every other day [63], to 100 mg/kg IV or SC daily for 3-4 weeks [43]. Both pentavalent antimonials are expensive and can induce side effects. Treatment with antimonials is considered especially risky when administered daily for more than 2 months to patients with either cardiac, renal, or hepatic insufficiency. During the therapy, a significant clinical improvement is usually noted but relapses are very common. Moreover, long-term treatment can induce resistance of Leishmania to pentavalent antimonials [64]. The value of aminosidine in CVL therapy is controversial because of its partial efficacy and high toxicity. Treatment with I.V. administration of liposomal amphotericin B resulted in clinical cure of CVL but almost all treated dogs remained positive for parasites in lymph nodes aspirates [65]. Allopurinol inhibits the growth of Leishmania spp. by blocking RNA synthesis. Allopurinol as a sole treatment for CVL was attempted in dosages of mg/kg/day P.O. for 2-24 months, and resulted in clinical cure, no adverse effects even in prolonged treatment periods, but relapses did occur [66, 67]. A

7 combination of allopurinol and antimony treatment (100mg/kg/day of meglumine and concurrent 30 mg/kg/day of allopurinol P.O.) until clinical remission, followed by maintenance treatment of allopurinol (20 mg/kg/day) for one week a month, resulted in clinical remission for a follow-up period of months [66]. In another study, dogs were followed for 5 years after being treated with a combination of these drugs for 1 month, followed by an 8 months period of treatment with 30 mg/kg/day allopurinol. These dogs were compared to dogs treated only with meglumine or allopurinol [68]. Dogs that received the combination therapy with allopurinol maintenance showed a significantly higher rate of clinical cure compared to the other groups. Although both studies showed prolonged clinical cure in dogs receiving this combination therapy, their parasitological status was not evaluated after treatment. Nevertheless, allopurinol is advantageous as a maintenance drug (can be given P.O., inexpensive, no major side effects even after extended periods of treatment), hence either the combination therapy of meglumine and allopurinol or solely allopurinol for long periods, seems to be the main therapy regimens that can be currently recommended for the treatment of CVL. Prevention And Control Since the dog is considered the major reservoir for HVL, campaigns to control CVL are usually aimed at reducing the risk of infection to people, rather than to protect dogs. The results of control efforts in Brazil designed to reduce the incidence of HVL by culling seropositive dogs have been disappointing [69, 70]. Mathematical methods which compared the effectiveness of various methods for controlling HVL and CVL indicated that spraying with insecticides would possibly be the most effective control method [71]. Evaluation of a deltamethrin collar for the control of sandfly bites in southern France showed protection of dogs from the majority of bites for a complete sandfly season [72]. Further research is needed to evaluate the effect of using this method in an endemic area on the prevalence of HVL as well. An effective vaccine against CVL or HVL is currently unavailable, although much research is being carried out in this area [73, 74]. Protection of the individual dog may include keeping the animal indoors from 1 hour before sunset to 1 hour after dawn during the vector season. Repellents and insecticides to stop the entry of sandflies into the house should also be used. Public Health Considerations Visceral leishmaniasis in humans is caused by the L. donovani subspecies (Table 1). Estimates indicate that these parasites are responsible for 500,000 cases of HVL annually among the 200 million people that are at risk for infection [1]. Sick people have hepatosplenomegaly, irregular fever, anemia, marked hypergammaglobulinemia, and a high mortality rate if untreated. The disease was traditionally present mostly in rural areas, but is now becoming more common in suburban and urban settings. The major risk group for HVL caused by L. infantum and L. chagasi has traditionally been young children and was often associated with malnutrition. With the emergence of HIV, the infection appeared in patients with AIDS and has been posing an important and often fatal secondary infection in immunocompromised people [75]. A recent report by the World Health Organization (WHO) indicated that people with AIDS have become the largest risk group for HVL in southern Europe, and that their coinfection is expected to present an increasing problem in areas were HIV and HVL overlap, especially in Brazil, Africa, and India [76]. The spread of leishmaniasis has also been demonstrated to occur by means of sharing needles by intravenous drug users [77]. This mode of infection threatens to extend the traditional boundaries of the disease in humans out of the regions where vector sandflies are present. In India and Sudan, HVL is caused by L. donovani and is thought to be an anthroponosis. In most other endemic areas of the world, HVL is mainly caused by L. infantum and L. chagasi, and is a zoonosis, with dogs and wild canids acting as the natural reservoirs for the parasites. However, some studies in Honduras and Brazil did not attribute significant risk for acquiring HVL in the presence of dogs [69, 70, 78, 79]. These studies suggest that in the New World dogs are not the major reservoirs and that the human-vector-human transmission is of greater importance. This was also one of the hypotheses in a study that examined if the elimination of the majority of seropositive dogs diminished the incidence of HVL [70]. Another possibility mentioned is that serology is not sufficient as a criterion for eliminating infected dogs. The elimination of seropositive dogs in the western society might not be an acceptable solution, as pets are considered an integral part of the family. Treatment of dogs presents a dilemma to veterinarians and public health officials in endemic areas, since in the presence of sandflies there is a remote risk of transmission of the disease from pets to members of the owner's family, and to other people in their community. In non-endemic areas, potential zoonotic foci can be created this way. References 1. Leishmaniasis control. Communicable Disease Surveillance and Response (CSR) WHO - 2. WHO: control of leishmaniasis. Report of a WHO expert committee. 1990; Shaw JJ. Taxonomy of the genus Leishmania: present and future trends and their implications. Mem Inst Oswaldo Cruz 1994; 89: PubMed - 4. Rioux JA, Lanotte G, Serres E, et al. Taxonomy of Leishmania. Use of isoenzymes. Suggestions for a new classification.

8 Ann Parasitol Hum Comp 1990; 65: PubMed - 5. Ashford DA, Bettini S. Ecology and epidemiology : Old World. In: Peters W and Killick-Kendrick R eds. The leishmanisis in biology and medicine, Orlando: Orlando Academic Press, 1987: Available from amazon.com - 6. Guessous-Idrissi N, Berrag B, Riyad M, et al. Short report: Leishmania tropica: Etiologic agent of a case of canine visceral leishmaniasis in northern Morocco. Am J Trop Med Hyg 1997; 57: PubMed - 7. Mauricio IL, Howard MK, Stothard JR, et al. Genomic diversity in the Leishmania donovanicomplex. Parasitology 1999; 119 (Pt 3): PubMed - 8. Nuwayri-Salti N, Nasr R, Haddad K, et al. Canine leishmaniasis in northern Lebanon. Ann Trop Med Parasitol 1997; 91: Deplazes P, Grimm F, Papaprodromou M, et al. Canine leishmaniosis in Cyprus due to Leishmania infantum MON 1. Acta Trop 1998; 71: PubMed Ozensoy S, Ozbel Y, Turgay N, et al. Serodiagnosis and epidemiology of visceral leishmaniasis in Turkey. Am J Trop Med Hyg 1998; 59: PubMed Baneth G, Dank G, Keren-Kornblatt E, et al. Emergence of visceral leishmaniasis in central Israel. Am J Trop Med Hyg 1998; 59: PubMed Ozbel Y, Turgay N, Ozensoy S, et al. Epidemiology, diagnosis and control of leishmaniasis in the Mediterranean region. Ann Trop Med Parasitol 1995; 89 (Suppl 1): PubMed Abranches P, Silva-Pereira MC, Conceicao-Silva FM, et al. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J Parasitol 1991; 77: PubMed Slappendel RJ. Canine leishmaniasis. A review based on 95 cases in The Netherlands. Vet Q 1988; 10: PubMed Diaz-Espineira MM, Slappendel RJ. A case of autochthonous canine leishmaniasis in The Netherlands. Vet Q 1997; 19: PubMed Swenson CL, Silverman J, Stromberg PC, et al. Visceral leishmaniasis in an English foxhound from an Ohio research colony. J Am Vet Med Assoc 1988; 193: PubMed Tesh RB. Control of zoonotic visceral leishmaniasis: is it time to change strategies? Am J Trop Med Hyg 1995; 52: PubMed Barnes JC, Stanley O, Craig TM. Diffuse cutaneous leishmaniasis in a cat. J Am Vet Med Assoc 1993; 202: PubMed Craig TM, Barton CL, Mercer SH, et al. Dermal leishmaniasis in a Texas cat [published erratum appears in Am J Trop Med Hyg 1987 Sep;37(2):414]. Am J Trop Med Hyg 1986; 35: PubMed Ozon C, Marty P, Pratlong F, et al. Disseminated feline leishmaniosis due to Leishmania infantum in Southern France. Vet Parasitol 1998; 75: PubMed Slappendel RJ, Greene CE. Leishmanisis. In: Greene CE ed. Infectious diseases of the dog and cat, Philadelphia: WB Saunders Co,1990; Hervas J, de Lara FC, Sanchez-Lsarria MA, et al. Two cases of feline visceral and cutaneous leishmaniosis in Spain. J Feline Med Sur 1999; 1: Squires KE, Schreiber RD, McElrath MJ, et al. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol 1989; 143: PubMed Liew FY, O'Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32: Kemp M, Kurtzhals JA, Kharazmi A, et al. Dichotomy in the human CD4+ T-cell response to Leishmania parasites. APMIS 1994; 102: PubMed Bogdan C, Gessner A, Solbach W, et al. Invasion, control and persistence of Leishmania parasites. Curr Op in Immunol 1996; 8: PubMed Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 1997; 175: PubMed Pinelli E, Killick-Kendrick R, Wagenaar J, et al. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 1994; 62: PubMed Killick-Kendrick R, Killick-Kendrick M, Pinelli E, et al. A laboratory model of canine leishmaniasis: the inoculation of dogs with Leishmania infantum promastigotes from midguts of experimentally infected phlebotomine sandflies. Parasite 1994; 1: PubMed Martinez-Moreno A, Moreno T, Martinez-Moreno FJ, et al. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Vet Immunol Immunopathol 1995; 48: PubMed Pinelli E, Gonzalo RM, Boog CJ, et al. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur J Immunol 1995; 25: PubMed Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Op in Immunol 1993; 5: PubMed -

9 33. Deplazes P, Smith NC, Arnold P, et al. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites. Parasite Immunol 1995; 17: PubMed Nieto CG, Garcia-Alonso M, Requena JM, et al. Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol 1999; 67: PubMed Bourdoiseau G, Bonnefont C, Hoareau E, et al. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 1997; 59: PubMed Baneth G, Kass PH, Jaffe CL. A comperative study of immunological, hematological and biochemical parameters in symptomatic and asymptomatic canine visceral leishmaniasis. In: Proceedings of the 9th Annual Congress of the European Society of Veterinary Internal Medicine, Perugia, Italy 1999; Lopez R, Lucena R, Novales M, et al. Circulating immune complexes and renal function in canine leishmaniasis. Zentralbl Veterinarmed [B] 1996; 43: PubMed Valladares JE, Ruiz DG, Riera C, et al. Study of haemostatic disorders in experimentally induced leishmaniasis in Beagle dogs. Res Vet Sci 1998; 64: PubMed Prats N, Ferrer L. A possible mechanism in the pathogenesis of cutaneous lesions in canine leishmaniasis. Vet Rec 1995; 137: Fondevila D, Vilafranca M, Ferrer L. Epidermal immunocompetence in canine leishmaniasis. Vet Immunol Immunopathol 1997; 56: PubMed Koutinas AF, Polizopoulou ZS, Saridomichelakis MN, et al. Clinical considerations on canine visceral leishmaniasis in Greece: a retrospective study of 158 cases ( ). J Am Anim Hosp Assoc 1999; 35: PubMed SCiaramella P, Oliva G, Luna RD, et al. A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum. Vet Rec 1997; 141: PubMed Slappendel RJ, Ferrer L. Leishmaniasis. In: Greene CE ed. Infectious diseases of the dog and cat, Philadelphia: WB Saunders Co 1998: Saunders - Available from amazon.com Rachamim N, Jaffe CL, Abranches P, et al. Serodiagnosis of canine visceral leishmaniasis in Portugal: comparison of three methods. Ann Trop Med Parasitol 1991; 85: PubMed Jaffe CL, McMahon-Pratt D. Serodiagnostic assay for visceral leishmaniasis employing monoclonal antibodies. Trans R Soc Trop Med Hyg 1987; 81: PubMed Mancianti F, Pedonese F, Poli A. Evaluation of dot enzyme-linked immunosorbent assay (dot-elisa) for the serodiagnosis of canine leishmaniosis as compared with indirect immunofluorescence assay. Vet Parasitol 1996; 65: PubMed Vercammen F, Berkvens D, Le Ray D, et al. Development of a slide ELISA for canine leishmaniasis and comparison with four serological tests. Vet Rec 1997; 141: PubMed Burns JM, Jr., Shreffler WG, Benson DR, et al. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. In: Proceedings of the Natl Acad Sci USA 1993; 90: PubMed Rhalem A, Sahibi H, Guessous-Idrissi N, et al. Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum. Vet Parasitol 1999; 81: PubMed Dye C, Vidor E, Dereure J. Serological diagnosis of leishmaniasis: on detecting infection as well as disease. Epidemiol Infect 1993; 110: PubMed Riera C, Valladares JE, Gallego M, et al. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 1999; 84: PubMed Rhalem A, Sahibi H, Lasri S, et al. Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment. Vet Immunol Immunopathol 1999; 71: PubMed Bourdoiseau G, Marchal T, Magnol JP. Immunohistochemical detection of Leishmania infantum in formalin-fixed, paraffin-embedded sections of canine skin and lymph nodes. J Vet Diagn Invest 1997; 9: Mathis A, Deplazes P. PCR and in vitro cultivation for detection of Leishmania spp. in diagnostic samples from humans and dogs. J Clin Microbiol 1995; 33: PubMed Ashford DA, Bozza M, Freire M, et al. Comparison of the polymerase chain reaction and serology for the detection of canine visceral leishmaniasis. Am J Trop Med Hyg 1995; 53: PubMed Reale S, Maxia L, Vitale F, et al. Detection of Leishmania infantum in dogs by PCR with lymph node aspirates and blood. J Clin Microbiol 1999; 37: PubMed Roura X, Fondevila D, Sanchez A, et al. Detection of Leishmania infection in paraffin-embedded skin biopsies of dogs using polymerase chain reaction. J Vet Diagn Invest 1999; 11: Le Blancq SM, Lanham SM, Evans DA. Comperative isoenzyme profiles of Old and New World Leishmania. In: Peters W and Killick-Kendrick R ed. The Leishmaniases in Biology and Medicine, London: Academic Press, 1987:

10 Available from amazon.com Belli A, Rodriguez B, Aviles H, et al. Simplified polymerase chain reaction detection of new world Leishmania in clinical specimens of cutaneous leishmaniasis. Am J Trop Med Hyg 1998; 58: PubMed Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res 1990; 18: PubMed Tibayrenc M, Neubauer K, Barnabe C, et al. Genetic characterization of six parasitic protozoa: parity between randomprimer DNA typing and multilocus enzyme electrophoresis. In: Proceedings of the Natl Acad Sci USA 1993; 90: PubMed Eisenberger CL, Jaffe CL. Leishmania: identification of Old World species using a permissively primed intergenic polymorphic-polymerase chain reaction. Exp Parasitol 1999; 91: PubMed Kontos VJ, Koutinas AF. Old world canine leishmaniasis. The Compendium of Continuing Education 1993; 15: Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol 1992; 86: PubMed Oliva G, Gradoni L, Ciaramella P, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995; 36: PubMed Ginel PJ, Lucena R, Lopez R, et al. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. J Small Anim Pract 1998; 39: PubMed Cavaliero T, Arnold P, Mathis A, et al. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 1999; 13: PubMed Denerolle P, Bourdoiseau G. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 1999; 13: PubMed Dietze R, Barros GB, Teixeira L, et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis 1997; 25: PubMed Ashford DA, David JR, Freire M, et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 1998; 59: PubMed Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 1996; 55: PubMed Killick-Kendrick R, Killick-Kendrick M, Focheux C, et al. Protection of dogs from bites of phlebotomine sandflies by deltamethrin collars for control of canine leishmaniasis. Med Vet Entomol 1997; 11: PubMed Eisenberger CL, Jaffe CL. Vaccines against Leishmaniasis. In: Levine MM, Woodrow GC, Kaper JB, et al, ed. New Generation Vaccines, New York; Basel; Hong Kong: Marcel Dekker, Inc.,1997: Rhalem A, Sahibi H, Guessous-Idrissi N, et al. Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum. Vet Parasitol 1999; 81: PubMed de Gorgolas M, Miles MA. Visceral leishmaniasis and AIDS. Nature 1994; 372: Desjeux P and UNAIDS. Leishmania and HIV in Gridlock. WHO/CTD/LEISH/98.9 Add. I, UNAIDS/ World Health Organization, Geneva, Switzerland. 77. Alvar J, Gutierrez-Solar B, Pachon I, et al. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol 1996; 14: Navin TR, Sierra M, Custodio R, et al. Epidemiologic study of visceral leishmaniasis in Honduras, Am J Trop Med Hyg 1985; 34: PubMed Costa CHN, Pereira HF, Pereira FCA, et al. Is the household dog a risk factor for American visceral leishmaniasis in Brazil? Trans R Soc Trop Med Hyg 1999; 93:464. All rights reserved. This document is available on-line at Document No. A